Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

Hyung Soon Park, Woo Sun Kwon, Sejung Park, Eunji Jo, So Jung Lim, Choong Kun Lee, Jii Bum Lee, Minkyu Jung, Hyo Song Kim, Seung Hoon Beom, Jun Yong Park, Tae Soo Kim, Hyun Cheol Chung, Sun Young Rha

Research output: Contribution to journalArticle

Abstract

Background: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. Methods: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). Results: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. Conclusions: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC.

Original languageEnglish
Article number268
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue number1
DOIs
Publication statusPublished - 2019 Oct 21

Fingerprint

Immunologic Monitoring
Body Fluids
Stomach Neoplasms
T-Lymphocytes
Vascular Endothelial Growth Factor A
Regulatory T-Lymphocytes
Interleukin-10
Cytokines
Chromosomal Instability
HLA-DR Antigens
Ascites
Neoplasms
Biomarkers
Fluorescence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Park, Hyung Soon ; Kwon, Woo Sun ; Park, Sejung ; Jo, Eunji ; Lim, So Jung ; Lee, Choong Kun ; Lee, Jii Bum ; Jung, Minkyu ; Kim, Hyo Song ; Beom, Seung Hoon ; Park, Jun Yong ; Kim, Tae Soo ; Chung, Hyun Cheol ; Rha, Sun Young. / Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. In: Journal for ImmunoTherapy of Cancer. 2019 ; Vol. 7, No. 1.
@article{2deac73120684194adadb90040355db6,
title = "Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer",
abstract = "Background: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. Methods: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). Results: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells ({\%}) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. Conclusions: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC.",
author = "Park, {Hyung Soon} and Kwon, {Woo Sun} and Sejung Park and Eunji Jo and Lim, {So Jung} and Lee, {Choong Kun} and Lee, {Jii Bum} and Minkyu Jung and Kim, {Hyo Song} and Beom, {Seung Hoon} and Park, {Jun Yong} and Kim, {Tae Soo} and Chung, {Hyun Cheol} and Rha, {Sun Young}",
year = "2019",
month = "10",
day = "21",
doi = "10.1186/s40425-019-0708-8",
language = "English",
volume = "7",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

Park, HS, Kwon, WS, Park, S, Jo, E, Lim, SJ, Lee, CK, Lee, JB, Jung, M, Kim, HS, Beom, SH, Park, JY, Kim, TS, Chung, HC & Rha, SY 2019, 'Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, 268. https://doi.org/10.1186/s40425-019-0708-8

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. / Park, Hyung Soon; Kwon, Woo Sun; Park, Sejung; Jo, Eunji; Lim, So Jung; Lee, Choong Kun; Lee, Jii Bum; Jung, Minkyu; Kim, Hyo Song; Beom, Seung Hoon; Park, Jun Yong; Kim, Tae Soo; Chung, Hyun Cheol; Rha, Sun Young.

In: Journal for ImmunoTherapy of Cancer, Vol. 7, No. 1, 268, 21.10.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

AU - Park, Hyung Soon

AU - Kwon, Woo Sun

AU - Park, Sejung

AU - Jo, Eunji

AU - Lim, So Jung

AU - Lee, Choong Kun

AU - Lee, Jii Bum

AU - Jung, Minkyu

AU - Kim, Hyo Song

AU - Beom, Seung Hoon

AU - Park, Jun Yong

AU - Kim, Tae Soo

AU - Chung, Hyun Cheol

AU - Rha, Sun Young

PY - 2019/10/21

Y1 - 2019/10/21

N2 - Background: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. Methods: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). Results: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. Conclusions: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC.

AB - Background: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. Methods: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). Results: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. Conclusions: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC.

UR - http://www.scopus.com/inward/record.url?scp=85073760372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073760372&partnerID=8YFLogxK

U2 - 10.1186/s40425-019-0708-8

DO - 10.1186/s40425-019-0708-8

M3 - Article

C2 - 31639056

AN - SCOPUS:85073760372

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 268

ER -